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Abstract
A rapid, simplified and highly efficient continuous-flow solid-phase peptide synthesis technology is reported for the direct synthesis
of mono and multiple N-methylated cyclic alanine and valine peptides. Through an optimization study, we find that only 1.5
equivalents of the amino acids are sufficient for the couplings to maintain excellent conversions. Importantly, the technology is
outstandingly sustainable, since three chemical steps are cancelled from the procedure and low amount of solvent is used, compared
to traditional technologies. Furthermore, it is also applicable to the coupling of challenging amino acids, since pentavalines were
constructed with high yield. The technology was successfully upscaled and peptide cyclization was carried out too.
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Introduction
Studying peptides has been the focus of research for
many years, because of the large variety of application
of these biomolecules in a number of fields, including
rational drug development [1–4], nanotechnology [5–8],
material science [9–12], etc. However, there are serious
limitations in the use of peptides in medicine. Major
obstacles are metabolic instability of peptides owing to
fast degradation by the proteases and peptidases in the
systemic circulation of the human body (short biological
half-life) and poor oral bioavailability [13–15]. Another
great drawback of peptides is their poor membrane per-
meability [16]. One of the synthetic modifications to
depress enzymatic cleavage and to insure facile absorp-
tion into the systemic blood circulation is the methyla-
tion of peptide backbone [17–19]. Peptides containing
N-methyl amino acids appear regularly in nature: in
plants, marine sponges and numerous microorganisms,
for example Cyclosporine A, with interesting pharmaco-
logical profile and therapeutic potential [20, 21]. The
importance of N-methylated peptides is warranted by
further significant biomedical applications too [22, 23].
Multiple N-methylated peptides are reluctantly ap-
plied [24] possibly due to the cumbersome and often
failed couplings of the amino acids onto sterically hin-
dered N-methylated sites [25] and incalculable confor-
mational changes [26, 27]. N-methylated peptides are
mainly synthesized in an indirect way by the on-resin
methylation of ordinary α-amino acids. The reason is
the relatively high price of Fmoc-protected N-methylated
amino acids, which excludes their direct utilization
thereof. Nonetheless, the in situ methylation requires
three additional time-consuming steps, extra reagents
and produces excess amount of waste. Moreover, during
Fmoc removal epimerizat ion and formation of
diketopiperazine [25] can occur. Even more problematic
is the spontaneous deprotection of the Fmoc-amino acid.
This is caused by the secondary amine functional group
of the N-terminus resulting in the additional incorpora-
tion of amino acids [28].
Continuous flow (CF) techniques have recently emerged as
a productive methodology in modern synthetic chemistry.
This is due to the substantial number of advantages against
conventional batch procedures, such as faster heat and mass
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transfer, the efficient mixing of substrates, shorter reaction
times and facile scale up [29–46].
In this work a fast and highly economic continuous-flow
solid-phase peptide synthesis (CF-SPPS) technique is present-
ed for the preparation of mono and multiple N-methylated
oligopeptides. The technology ensures high yields for the de-
sired peptides with the aid of readily available Fmoc-protected
N-methylated amino acids applied in 1.5 M excess.
Importantly, the method requires a considerably shorter time,
while lower amount of waste is produced. Mono and multiple
N-methylated oligoalanines and oligovalines were synthe-
sized as model peptides including difficult sequences.
Results and discussion
Fmoc-protected N-methylated peptides are available on the
market, thus their direct and cost-efficient incorporation into
peptides is of considerable current interest. For this purpose,
the highly efficient CF-SPPS method developed by our labo-
ratory [35] is utilized and modified to ensure complete con-
versions for N-methylated sequences. The CF reactor used in
this study (Fig. 1) consists of an HPLC pump, an HPLC
autosampler, an HPLC column thermostat with a cylindrical
PEEK column and a back-pressure regulator. For optimization
of the CF-SPPS coupling conditions, an N-methylated amino
acid, Fmoc-protected N-methyl alanine (N-Me-Ala) 1 was
coupled to the Tentagel resin-bound alanine tetrapeptide 2,
with fine-tuning of the most important continuous-flow reac-
tion parameters.
For the initial screening, the PEEK column was filled with
200 mg of 2. It was placed into the column thermostat that can
be heated up to a maximum of 100 °C. A back-pressure valve
was fitted into the flow line to provide constant pressures up to
Fig. 1 Schematic illustration of
the used CF apparatus
Scheme 1 The test reaction used for the fine-tuning of CF-SPPS
coupling conditions. i) 1.5 equiv. of HATU, 3 equiv. of DIEA in DMF;
ii) 2% DBU and 2% piperidine in DMF; iii) 90% TFA + 10% H2O
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Scheme 2 The solution phase cyclization of N-methylated oligomer 7
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100 bar. The HPLC pump ensured a continuous stream of the
reaction mixture at flow rates of 0.01–1.0 mL min−1. 1.5
e qu i v a l e n t s ( e q u i v. ) o f t h e c oup l i n g r e ag e n t
1-[bis-(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b-
]pyridinium-3-oxide (HATU) to form the active esters and 3
equiv. of N,N-diisopropylethylamine (DIEA) in 1 mL DMF
was used to couple Fmoc-N-Me-Ala-OH to the resin-bound
tetrapeptide 2 (Scheme 1). The deprotection step was per-
formed by using 1 mL of deprotection solution (2% piperidine
and 2% 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in N,N-
dimethylformamide (DMF)). Between the two chemical steps,
the system was washed for 10 min with DMF (Scheme 2).
A complete reaction parameter screening process was
carried out, in order to attain the best conversion. First
the temperature dependence of the coupling reaction was
investigated. Increasing the temperature to 60 °C resulted in
>90% conversion (Supporting Information, Table 1), but
further increases led to lower conversions. This can be
accounted for the degradation of the active ester [47].
Thus, 60 °C was taken as an optimal value. On examina-
tion of the pressure dependence at 60 °C, acceptable con-
version was achieved at 80 bar (Supporting Information,
Table 2). A flow rate effect scan was performed at 60 °C
and 80 bar. The best result was obtained at 0.15 mL min−1
(Supporting Information, Table 3). To fine-tune the amount
of the amino acid, the peptide synthesis was performed at
60 °C, 80 bar and 0.15 mL min−1. 1.5 equiv. was satisfac-
tory to maintain 97% conversion, but reducing this ratio
resulted in poorer results (Supporting Information,
Table 4). Finally, we turned our attention towards optimiz-
ing the concentration of the coupling medium. The results
indicated that the lower the concentration of the coupling
mixture, the higher the conversion. The test reaction was
complete only at a concentration of 0.011 mM (Supporting
Information, Table 5). On the basis of earlier results [35],
the volume of the deprotection solution was 2 mL applied
with a flow rate of 0.15 mL min−1. The results of the
reaction parameter optimization are shown in Fig. 2.
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Fig. 2 The effect of temperature (a), pressure (b), flow rate (c), amino acid equivalents (d) and coupling mixture concentration on the conversion for the
test reaction shown on Scheme 1
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The optimized CF-SPPS technique might allow
accomplishing the fast and powerful synthesis of numerous
N-methylated peptides on solid support. As an evidence of the
effectiveness of the procedure, mono and multiple N-methyl-
ated pentaalanine peptides were prepared. Oligoalanine pep-
tides containing one or more methyl groups can be employed
as template structures for designing biologically active
compounds.
The N-methylated alanine pentapeptides were designed to
have 1D- and 4 L–amino acids to afford a subsequent future
efficient cyclization [26, 48]. Four different pentaalanine
structures were created containing 1, 2, 3 or 4 N-methylated
peptide bonds. The synthesized structures are shown in
Table 1.
The Fmoc-Ala loaded resin was filled into the PEEK col-
umn. The coupling and deprotection steps were performed
under the conditions optimized previously. After the synthesis
the resin was transferred to a flask and the cleavage was car-
ried out by the utilization of 90% trifluoroacetic acid (TFA)
and 10% water. The crude peptides were analyzed by HPLC-
MS and the yields are shown in Table 1. Importantly, the
yields of the peptides are >90% and no truncated sequences
were found in the product. The yields were calculated from
resin loading. Outstandingly, no extra amino acid incorpora-
tion was detected resulting from the spontaneous deprotection
of the activated amino acid. This fact can be explained by the
short residence time of the coupling mixture spent on the resin
bed compared to ordinary SPPS technologies and by the fast
and efficient coupling of the amino acid to the peptide chain.
The residence time was measured to be 5.8 min.
Since coupling efficiencies and raw purities were accept-
able for alanine peptides, the technology was tested on diffi-
cult sequences. Peptides containing high number of valines
residues are known as difficult sequences [49]. Thus
pentavalines containing 1, 2, 3, and 4 N-methylated amino
acid building blocks were also synthesized. The structure of
pentavalines prepared is shown in Table 2. The synthesis of
oligovalines 9–12 was carried out under the conditions opti-
mized previously. Acceptable yield was achieved only for
oligomer 9, which contains only 1 N-methylated amino acid.
Table 1 The synthesized N-methylated oligoalanines and obtained yields
entry structure yield (%)
1 >95
5
2 94
6
3 94
7
4 92
8
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For oligomer 10 the yield was considerably lower. Moreover,
oligopeptides 11 and 12were not isolated at all. Oxyma pure is
known as a superior peptide coupling reagent compared to
benzotriazole-based compounds [50]. Therefore, the synthesis
of oligomers 10–12 was carried out by the utilization of 1.5
equiv. of oxyma pure and 1.5 equiv. of DIC as coupling agents
in the presence of 1.5 equiv. of amino acids. This coupling
strategy considerably increased the yield of the resulting olig-
omer 10 (>95%). However, for 11 and 12 it remained ~86%
and ~78%, respectively, which is a reasonable value. To our
delight, however, the yield could be further enhanced only by
the utilization of 2 equiv. of the amino acids, providing the
desired high values of 94% and 91% for oligomer 11 and 12,
respectively. Importantly no diketopiperazine formation was
observed for peptides 8 and 12, which contain N-methylated
amino acids in the second position. The yields were calculated
from resin loading.
N-methylated peptides mainly occur as cyclic peptides [26,
27, 48]. Therefore, oligomer 7 was selected for a cyclization
experiment.
The synthesis of 7was successfully scaled up to 0.15mmol
value and the peptide was isolated with 93% yield. The results
of the synthesis are superior than those for the earlier ones
(Table 3).
Importantly, our methodology required lower amounts of
amino acid for coupling (1.5 equiv.) making the synthesis
more cost-effective. Noteworthy, the coupling and
deprotection times were 28 min under flow conditions, com-
pared with 274 min in the former strategy. With this CF tech-
nique an amount of only 4.2 mL of solvent was used, as
compared with the high solvent consumption (66 mL) of the
original approach. Importantly, 3 additional chemical steps
were avoided. Importantly, the technology is not only faster,
but considerably more sustainable.
Table 2 The investigated oligovalines and yields of the syntheses
entry structure
crude purity 
(%)
1 93
9
2 >95a
10
3 94b
11
4 91b
12
a Oxyma was used as coupling agent
b Oxyma was used as coupling agent by the utilization of 2 equiv. of amino acids
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Easy and effective solution-phase cyclization of peptides
can be carried out by means of a dual syringe pump utilizing
the pseudo-high dilution peptide cyclization technology
[51–54]. In a typical experiment, a solution of 1 equiv. of
linear peptide in 10 mL DMF was transferred into a syringe.
To the equal volume of DMF 1 equiv. of HATU was added
and poured into another syringe. Both reaction mixtures were
infused into a vigorously stirred solution of 3 equiv. of DIEA
in 40 mL DMF at a flow rate of 0.015 mL min−1. After com-
pletion, the mixture was stirred for 30 min. The reaction mix-
ture was diluted with 50 mL water and lyophilized. The con-
version and the purity of the crude cyclic peptide was deter-
mined by RP-HPLC-MS analysis. The conversion of the cy-
clization experiment was quantitative and the RP-HPLC puri-
fication provided 68% yield from resin loading for peptide 13.
It is a considerably higher value than the published result
(26%) [48].
Conclusion
In summary, a rapid, simplified and highly efficient CF-SPPS
technology is reported for the direct synthesis of mono and
multiple N-methylated cyclic alanine and valine peptides.
Through an optimization study, we find that in general only
1.5 equivalents of the amino acids are sufficient for the cou-
plings to maintain excellent conversions. This is a cheap and
time-efficient approach requiring low amounts of solvents and
reagents. Furthermore, it is also applicable to the coupling of
challenging amino acids. Importantly, the peptides were syn-
thesized directly, avoiding the on-resin methylation of the
amino acids, which allows shortening the synthesis by three
chemical steps. Mono and multiple N-methylated
pentaalanines and pentavalines were prepared as model and
difficult sequences respectively. In the case of alanines, the
results were satisfactory under the optimized conditions. To
obtain excellent crude purities of pentavalines, however, re-
quired the use of oxyma pure as coupling agent and 2 equiv-
alents of amino acids. A scaled-up synthesis was also per-
formed and a subsequent cyclization of the peptide utilizing
the pseudo-high dilution solution-phase technology was car-
ried out too.
Experimental (materials and methods)
Peptide synthesis: The linear peptide chains were extended
on a Tentagel R PHB resin (0.20 mmol g−1). For CF experi-
ments, a modular CF apparatus was assembled, consisting of a
cylindrical PEEK column (with internal dimensions of 100 ×
4 mm) filled with the amino acid loaded resin (200 mg), an
HPLC pump (JASCO PU-880), an HPLC autosampler
(JASCO AS-2055 Plus), an HPLC column thermostat
(Dionex STH 585), and a backpressure regulator (Upchurch
Scientific/IDEX Health & Science P-465 PEEK). A coupling
mixture consisting of 1.5 equivalents of Fmoc-protected ami-
no acid and 1.5 equivalents of HATU as coupling reagent
dissolved in 1 mLDMF and 3 equivalents of DIEAwas mixed
by the autosampler. The coupling mixture has been prepared
just before the coupling reaction. The coupling reactions were
carried out at the optimized reaction conditions, 80 bar pres-
sure, 60 °C temperature, 0.15 mL min−1 flow rate. For Fmoc
deprotection 2 mL of 2% DBU 2% piperidine DMF solution
has been used. Between two chemical steps for washing DMF
has been used for 6 min long with 0.15 mL min−1 flow rate.
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